Plus, since 2018, another $20mln (appx) has been added onto capitalised exploration expenses - so, further Value added.
Just to liven the BB up, back in March 2018, when the Co was floated (5 years exactly!), the SP was 10p and no of shares 860mln appx; therefore the Mkt Cap was 86 million. The EPC was supposedly 1 year away (or so). Today, 5 years later, with EPC almost done, + extra Optimisation Study done, +further engineering design works by POWERCHINA, why is the Mkt cap just 20mln?
The EPC is 6 weeks away, should we expect an SP uplift when announced? And if yes, to how much? Would going back to 86mln be unreasonable to expect i.e. 4-5x uplift?
All comments welcome! GLA
You are right, wary is the right word. Mkt knows the potential (incl. Unilever) BUT they want to see numbers and cash flowing in; hopefully, we will get these soon.
Plus, I don't understand people's (genuine?) fears about a fund raise; Co has cash until December, in a worst case scenario, by then a lot more deals will be announced, more projects will be closer to fruition etc, hence it's logical to assume that the SP will be higher; even if at 2-3p (IMO, conservative), the Mkt cap will be over 10 mln so even a 1mln raise (remember, the Co expects 6mln Revenues for FY2024 i.e. July24-to-June25) would only be a 10% dilution.
Yes, we need some numbers; however, the Co is progressing step by step towards completing many projects simultaneously, therefore Mgt might not be too worried about the cashflow right now but instead focus on completions; plus, the highly rewarding Options' Scheme for Directors and Employees (kicking off around September for FY23 Results) probably means that they don't need to spend their cash now on Share purchases, especially if they are confident of achieving their targets.
Personally, I'd rather see Mgt focus on sales/new business/successful project completions, than have them worrying about the daily ups and downs of the SP. Another 2-3 big RNSs should make people stop worrying IMO; until then, enjoy buying at this incredible SP.
We'll get there Fboy, after a few more good RNSs, but I think it's unlikely today, especially for the stock to run out. Though I hope I am 100% wrong on this :)
David,
I agree, the SP is kept low because of the shocking events of last year and also, the lack of hard numbers in the recent RNSs.
Hopefully, the next ones will have some numbers for the Market to digest.
Good luck to you too, Iceman.
David, I partly agree with the no details part, but remember these new technologies are highly confidential and have to remain so, for Unilever to get a first-mover advantage; this has been already a 2-year project, with more to come obviously and Unilever would not partner with APTA if they had doubts about the long-term; also remember that the Co mentioned a few weeks ago about 6-8mn of medium term deals for potential closing, this could be one of them; the other being - possibly (just MO) - the top5 pharma partner for the IHC collaboration via Optimer + platform (more news maybe on Wednesday).
Iceman, nobody can time the market; just buy small lots every month and you will not get caught out.
The SP is near all time lows and there is plenty of newsflow to come in the next few months.
Iceman,
Pls read the RNSs; the Co announced end of January they had 2.1 mln cash; and in their November presentation, they specified a monthly cash burn of 285k.
Assuming you are not a shorter, the Co had 2.1 mln at end of January, with a monthly cash burn of 285k i.e. 7 months hence, taking us to August 2024; in addition, gross income from H124 Sales (between 1.5-2.5) gives it another 700-1.3mln, so extra 3-5 months; and this ignores any income from Jan-to-June 2024, or to Dec.2024 when the definite cash could possibly run out.
Iceman,
Can u pls enlighten the rest of us? You ask how much cash is left, whilst saying with a lot of certainty "hate to buy JUST before placing"...so, where have you based this assertion?
If no RNSs were forthcoming, you'd probably say, "no news, no activity, a placing is imminent"?
If RNSs come, you say "these companies send out news to pump the price before a big placing"
So I guess, you can't lose, can you?
This will be huge, IMO, as more Unilever-like companies will get interested (and become APTA clients hopefully).
And we still have Wednesday to look out for!
Otherwise, why specify an exact time, 2 hours after mkt open on the 13th, for a simple presentation?
"A pre-recorded webcast from Dr David Bunka, Chief Scientific Officer of Aptamer Group, reviewing the Optimer®+ platform and the technical progress to date, will be available on the Aptamer Group website from 10:00am (UCT) on 13 March, 2024, at: https://aptamergroup.com/investors/reports-and-presentations/."
Unless I am missing something?
From previous RNSs: July 2022 -- Contracts signed with a top five pharmaceutical company to develop multiple Optimer® binders as immunohistochemistry (IHC) reagents to support pipeline development and early discovery targets; March 2023-- Optimer®-Fc tools launched to enable immunohistochemistry research and diagnostic workflows; Aug. 23--Signed two deals with a top five pharma partner, valued at up to £0.2 million for the development of tools for use in immunoassays and IHC in detecting neuronal targets; "The first contract is for the development of an Optimer pair to a neurodegenerative biomarker for use in an immunoassay platform. The second contract is a follow-on contract for the final stage of Optimer development to a neuronal protein target for immunohistochemistry (IHC), following positive results in the earlier stages of Optimer development. This builds on the adoption of our Optimer-Fc platform for use in automated IHC workflows."
And the last RNS of 27 Febr 24 -- "Both the lab-based research and the initial animal experiments suggest that Optimer®+ will be well placed to deliver the next generation of binders to enable the targeted delivery of precision medicines. This is an area where we are seeing increasing interest due to the unmet needs across gene therapy and precision chemotherapy."
My theory? APTA has been working flat out on this platform, Optimer + for a full year, and with this "top5 pharma partner" (AstraZeneca??) for at least 2 years, so I dare say that something will be announced on the 13th with respect to new collaborations, or scientific breakthroughs; otherwise, why ringfence scarce R&D cash to spend on Optimer+, if this existing collaboration was not close to bearing fruit?
All in my biased opinion, as usual. Good luck to LTHolders!
@FrBoy,
If I were the Mgt, I might be saving something to announce next week, to coincide with this below eg a new contract for this service;"A pre-recorded webcast from Dr David Bunka, Chief Scientific Officer of Aptamer Group, reviewing the Optimer®+ platform and the technical progress to date, will be available on the Aptamer Group website from 10:00am (UCT) on 13 March, 2024, at: https://aptamergroup.com/investors/reports-and-presentations/."
Let's also hope that there will be more traction and +ve publicity on the 13th of March, re the below:
"A pre-recorded webcast from Dr David Bunka, Chief Scientific Officer of Aptamer Group, reviewing the Optimer®+ platform and the technical progress to date, will be available on the Aptamer Group website from 10:00am (UCT) on 13 March, 2024, at: https://aptamergroup.com/investors/reports-and-presentations/."
Let's not worry about the daily volatility, we know the future is bright (blue!), we just need the Market to see 2-3 big contracts in the next month or two. It's a matter of patience now and holding our nerve until then.
BTW, SP up by about 20-25% from the bottom is not much to write home about; some people may still take profits but they may regret it, hopefully!
GLA
But no Heavy Buying either :) -- for now!